135 related articles for article (PubMed ID: 11259637)
1. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
2. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
3. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Rao S; Aoyama R; Schrag M; Trager WF; Rettie A; Jones JP
J Med Chem; 2000 Jul; 43(15):2789-96. PubMed ID: 10956186
[TBL] [Abstract][Full Text] [Related]
4. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Afzelius L; Zamora I; Masimirembwa CM; Karlén A; Andersson TB; Mecucci S; Baroni M; Cruciani G
J Med Chem; 2004 Feb; 47(4):907-14. PubMed ID: 14761192
[TBL] [Abstract][Full Text] [Related]
5. Development of a combined protein and pharmacophore model for cytochrome P450 2C9.
de Groot MJ; Alex AA; Jones BC
J Med Chem; 2002 May; 45(10):1983-93. PubMed ID: 11985466
[TBL] [Abstract][Full Text] [Related]
6. Homology modeling and substrate binding study of human CYP2C9 enzyme.
Payne VA; Chang YT; Loew GH
Proteins; 1999 Nov; 37(2):176-90. PubMed ID: 10584064
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
8. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles.
Spatzenegger M; Wang Q; He YQ; Wester MR; Johnson EF; Halpert JR
Mol Pharmacol; 2001 Mar; 59(3):475-84. PubMed ID: 11179442
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.
Jones JP; He M; Trager WF; Rettie AE
Drug Metab Dispos; 1996 Jan; 24(1):1-6. PubMed ID: 8825183
[No Abstract] [Full Text] [Related]
10. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
[TBL] [Abstract][Full Text] [Related]
11. Comparative QSAR analyses of competitive CYP2C9 inhibitors using three-dimensional molecular descriptors.
Lather V; Fernandes MX
Chem Biol Drug Des; 2011 Jul; 78(1):112-23. PubMed ID: 21477091
[TBL] [Abstract][Full Text] [Related]
12. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
Lewis DF
Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
[TBL] [Abstract][Full Text] [Related]
13. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors.
Afzelius L; Masimirembwa CM; Karlén A; Andersson TB; Zamora I
J Comput Aided Mol Des; 2002 Jul; 16(7):443-58. PubMed ID: 12510879
[TBL] [Abstract][Full Text] [Related]
14. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
[TBL] [Abstract][Full Text] [Related]
15. Construction of a 3D model of cytochrome P450 2B4.
Chang YT; Stiffelman OB; Vakser IA; Loew GH; Bridges A; Waskell L
Protein Eng; 1997 Feb; 10(2):119-29. PubMed ID: 9089811
[TBL] [Abstract][Full Text] [Related]
16. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
[TBL] [Abstract][Full Text] [Related]
18. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.
Ridderström M; Zamora I; Fjellström O; Andersson TB
J Med Chem; 2001 Nov; 44(24):4072-81. PubMed ID: 11708911
[TBL] [Abstract][Full Text] [Related]
19. Homology model of 1alpha,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): active site architecture and ligand binding.
Gomaa MS; Simons C; Brancale A
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):53-60. PubMed ID: 17240137
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutagenesis of mouse steroid 7 alpha-hydroxylase (cytochrome P-450(7) alpha): role of residue-209 in determining steroid-cytochrome P-450 interaction.
Iwasaki M; Lindberg RL; Juvonen RO; Negishi M
Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):569-73. PubMed ID: 8484736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
